JosephDavidMeserveMD

Hospital Medicine/Hospitalist

Physician

Dr. Meserve is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3 Richland Medical Park Dr
Ste 120
Columbia, SC 29203
Phone+1 803-434-8866

Fax+1 803-933-3049

University of California (San Diego) Medical CenterResidency, Internal Medicine, 2015 - 2018
Medical University of South CarolinaClass of 2015

PubMed

50 citations
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, Prianka Chilukuri, Joseph Meserve
Inflammatory Bowel Diseases. 2018-10-12
47 citations
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
Joseph Meserve, Antonio Facciorusso, Ariela K. Holmer, Vito Annese, William J. Sandborn
Alimentary Pharmacology & Therapeutics. 2021-02-01
56 citations
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.
Joseph Meserve, Satimai Aniwan, Jenna L. Koliani-Pace, Preeti Shashi, A Weiss
Clinical Gastroenterology and Hepatology. 2019-07-01

Journal Articles

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature